Wire · opportunities
FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic for Polycythemia Vera
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
The FDA has approved rusfertide (Mimrylo), the first-in-class hepcidin mimetic designed to regulate iron and control erythrocytosis in adults with polycythemia vera.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new regulatory pathway opened by the FDA’s approval of this novel hepcidin mimetic for polycythemia vera, which could shorten time to market if your biotech targets iron regulation or related hematologic conditions.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalpolycythemia-verahepcidin-mimeticdrug-approval